Intervention
sitagliptin
ClinicalTrials.gov intervention label
Clinical trials
44 shownEfficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.NCT02849080 · 2016-09-20
COMPLETEDEfficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesNCT02607865 · 2016-02-15
COMPLETEDA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 DiabetesNCT02254291 · 2014-10-02
COMPLETEDInfluence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass SurgeryNCT02336659 · 2014-04-01
COMPLETEDA Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenNCT02077946 · 2014-02-10
COMPLETEDEfficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and MetforminNCT01907854 · 2013-12-02
COMPLETEDEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 DiabetesNCT01930188 · 2013-12-02
COMPLETEDThe Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 DiabetesNCT02008682 · 2013-12-01
COMPLETEDEffects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin TherapyNCT01859793 · 2013-06-01
COMPLETEDCorrelation Between Plasma- and Endothelial DPP-4 ActivityNCT02192853 · 2013-05-01
COMPLETEDA Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesNCT01455870 · 2013-05-01
COMPLETEDA Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesNCT01455909 · 2013-02-01
WITHDRAWNTreatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and MetforminNCT01519674 · 2012-06-01
COMPLETEDSitagliptin in Type I Diabetic PatientsNCT01741103 · 2011-06-01
WITHDRAWNComparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)NCT01296412 · 2011-03-11
COMPLETEDSitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesNCT01260246 · 2010-12-01
TERMINATEDChanges in Bone Turnover With Increased Incretin Hormone ExposureNCT01374568 · 2010-07-01
TERMINATEDA Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.NCT01098539 · 2010-05-01
COMPLETEDSitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin TreatmentNCT01100125 · 2010-04-01
COMPLETEDEffect of Sitagliptin on Postprandial Lipoprotein MetabolismNCT00939939 · 2010-03-01
TERMINATEDSitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2DNCT02607410 · 2010-01-01
COMPLETEDComparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With InsulinNCT01046110 · 2010-01-01
COMPLETEDProtective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)NCT01159847 · 2010-01-01
COMPLETEDSafety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of MetforminNCT00998686 · 2009-11-01
TERMINATEDStudy to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal ImpairmentNCT00958269 · 2009-08-01
TERMINATEDEffect of Sitagliptin on Graft Function Following Islet TransplantationNCT00853944 · 2009-07-01
TERMINATEDA Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)NCT00888238 · 2009-05-12
COMPLETEDEfficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesNCT00838903 · 2009-02-01
COMPLETEDThe Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)NCT00832624 · 2008-11-26
TERMINATEDSafety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)NCT00676338 · 2008-11-01
COMPLETEDEffect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 DiabetesNCT00789191 · 2008-11-01
COMPLETEDSitagliptin in Renal Transplant RecipientsNCT00740363 · 2008-09-01
COMPLETEDSafety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)NCT00770081 · 2008-09-01
COMPLETEDBI 10773 add-on to Metformin in Patients With Type 2 DiabetesNCT00749190 · 2008-08-01
COMPLETEDComparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneNCT00729326 · 2008-08-01
COMPLETEDThe Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusNCT00700817 · 2008-06-01
COMPLETEDThe Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and InflammationNCT00696982 · 2008-06-01
UNKNOWNA Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)NCT00701090 · 2008-05-01
COMPLETED18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)NCT00666458 · 2008-04-01
COMPLETEDA Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)NCT00637273 · 2008-01-01
COMPLETEDA Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusNCT00477581 · 2007-05-01
COMPLETEDEffect of Januvia on Beta Cell Function in Patients With Diabetes MellitusNCT00425490 · 2007-01-01
COMPLETEDSitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)NCT00350779 · 2006-06-12
COMPLETEDAn Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)NCT00095056 · 2004-10-01
COMPLETEDCommon conditions
Diabetes Mellitus, Type 217Diabetes13Type 2 Diabetes Mellitus11Type 2 Diabetes4Diabetes Mellitus Type 22Arterial Stiffness1Atherosclerosis1Chronic Renal Insufficiency1Diabetes Mellitus1Diabetes Mellitus Non-insulin-dependent1Diabetes Mellitus, Non-Insulin-Dependent1Diabetes Type I1Glucose Intolerance1Islet Transplantation1Nonalcoholic Steatohepatitis1Renal Impairment1Renal Insufficiency1Severe Obesity1Type 1 Diabetes1Type 2 Diabetes Mellitus, Non Insulin Dependent1
Leading sponsors
Novo Nordisk A/S11Merck Sharp & Dohme LLC6AstraZeneca5GlaxoSmithKline2Intarcia Therapeutics2Phenomix2Assaf-Harofeh Medical Center1Boehringer Ingelheim1European Foundation for the Study of Diabetes1Hvidovre University Hospital1London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1Ludwig-Maximilians - University of Munich1Medical College of Wisconsin1Novartis1Seoul National University Bundang Hospital1
Trial status mix
COMPLETED34
TERMINATED7
WITHDRAWN2
UNKNOWN1
Phase mix
PHASE323
PHASE413
NA4
PHASE12
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.